Stay updated on Safety of Doxorubicin & Pembrolizumab in Sarcoma Clinical Trial
Sign up to get notified when there's something new on the Safety of Doxorubicin & Pembrolizumab in Sarcoma Clinical Trial page.

Latest updates to the Safety of Doxorubicin & Pembrolizumab in Sarcoma Clinical Trial page
- Check4 days agoNo Change Detected
- Check11 days agoNo Change Detected
- Check18 days agoChange DetectedRevision updated from v3.5.3 to v3.5.4 on the page. This appears to be a small metadata or formatting update and does not modify study details, eligibility criteria, or results.SummaryDifference0.1%

- Check24 days agoNo Change Detected
- Check39 days agoChange DetectedThe page’s ClinicalTrials.gov UI/version footer was updated from **v3.5.2** to **v3.5.3**, indicating a site revision rather than a change to the study record content.SummaryDifference0.1%

- Check46 days agoChange DetectedPage revision updated from v3.5.0 to v3.5.2.SummaryDifference0.1%

- Check60 days agoChange DetectedAdded the related MeSH term 'Primary interstitial lung disease specific to childhood' to the page's related topics/MeSH terms.SummaryDifference0.1%

- Check75 days agoChange DetectedThe page revision header was updated from v3.4.3 to v3.5.0.SummaryDifference0.1%

- Check82 days agoChange DetectedPage revision updated to v3.4.3; the previous revision v3.4.2 was superseded.SummaryDifference0.1%

Stay in the know with updates to Safety of Doxorubicin & Pembrolizumab in Sarcoma Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Safety of Doxorubicin & Pembrolizumab in Sarcoma Clinical Trial page.